Oculus shares rocket up on gel approval; Bharat launches Ph3 heart drug trial; Pervasis gains fast track;

@FierceBiotech: AZ's oral prostate cancer drug fails another Phase III trial. News | Follow @FierceBiotech

@JohnCFierce: AZ and Wellpoint are teaming up on comparative effectiveness studies. If the government won't do it, private payers will. News |  Follow @JohnCFierce 

> Shares of Oculus Innovative Sciences shot up this morning after the developer reported that the FDA has approved a new gel to treat skin inflammation. Story

> India's Bharat Biotech has launched a Phase III study of THR-100, a potential blockbuster heart drug licensed from ThromboGenics. Story

> Pervasis Therapeutics says that the FDA has granted fast track review status for Vascugel for the prevention of hemodialysis access failure in patients with end stage renal disease. Pervasis release

> Galapagos NV reports that it has received 4 million euros in milestone payments under its pact with Servier. Report

And Finally...Three-year-olds who eat a steady diet of processed foods are likely to see their IQs slip significantly behind children who receive more nutritious foods. Story